Multiple Sclerosis Clinic
The Multiple Sclerosis Clinic evaluates and treats a large number of patients with multiple sclerosis and other neuroimmunological disorders.
The MS team comprises two neurologists or neuroimmunologists, an MS neurology fellow, an MS nurse, and a study coordinator. The team also includes additional study coordinators and research associates.
Our researchers have developed new drugs that have shown promise as future treatments for MS. Patients are able to participate in several clinical trials, which are designed to test these and other new therapies to manage MS. The studies that are currently enrolling at UC Davis are listed below.
Open Studies Currently Enrolling New Participants at UC Davis
A Multicenter, randomized, rater-and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatiramer acetate 20 mg s.c. in patients with RRMS
For more information, enter NCT01633112 into the search box at www.clinicaltrials.gov.
A Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of rHIgM22 in patients with all clinical presentations of MS
For more information, enter NCT01803867into the search box at www.clinicaltrials.gov.
A Phase 2/3 Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
For more information, enter NCT01628393 into the search box at www.clinicaltrials.gov.
A Phase 1 Randomized Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis
For more information, enter NCT01585766 into the search box at www.clinicaltrials.gov.
A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
For more information, enter NCT01665144 into the search box at www.clinicaltrials.gov.
If you are interested in participating or want more information on our current clinical trials, please contact:
Janelle Butters, RN, at (916) 734-6276 or by email: Janelle.Butters@ucdmc.ucdavis.edu